GLP-1 agonists (Table 1) activate GLP-1 receptors located in multiple organs, including the pancreas, gastrointestinal tract, and brain, which potentiate glucose-stimulated insulin secretion and assist in diabetic control [4,5,6]
In studies targeting adult neurogenic processes, however, longer chow treatment will result in a more heterogenous population of recombined cells at different stages of differentiation
Patients with irregular schedules preventing consistent morning dosing, cognitive limitations affecting complex medication routines, or lack of understanding about administration requirements may be directed toward injectable alternatives with simpler once-weekly protocols
The FDA reviewed these reports and found no clear connection between GLP-1 medications, such as semaglutide, and mood changes